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ABSTRACT 
BACKGROUND End-of-day questionnaires, which are considered the gold standard for 
assessing abdominal pain and other gastrointestinal (GI) symptoms in irritable bowel 
syndrome (IBS), are influenced by recall and ecological bias. The Experience Sampling 
Method (ESM) is characterized by random and repeated assessments in the natural state and 
environment of a subject, and herewith overcomes these limitations. This report describes the 
development of a patient-reported outcome measure (PROM) based on the ESM-principle, 
taking into account content validity and cross-cultural adaptation.   
METHODS Focus group interviews with IBS patients and expert meetings with international 
experts in the fields of neurogastroenterology & motility and pain were performed in order to 
select the items for the PROM. Forward-and-back translation and cognitive interviews were 
performed to adapt the instrument for the use in different countries and to assure on patients’ 
understanding with the final items.  
KEY RESULTS Focus group interviews revealed 42 items, categorized into five domains: 
physical status, defecation, mood and psychological factors, context and environment, and 
nutrition and drug use. Experts reduced the number of items to 32 and cognitive interviewing 
after translation resulted in a few slight adjustments regarding linguistic issues, but not 
regarding content of the items.  
CONCLUSIONS AND INFERENCES An ESM-based PROM, suitable for momentary 
assessment of IBS symptom patterns was developed, taking into account content validity as 
well as cross-cultural adaptation. This PROM will be implemented in a specifically designed 
smartphone application and further validation in a multicenter setting will follow. 
 
KEYWORDS: Irritable bowel syndrome, abdominal pain, GI symptoms, experience sampling 
method, momentary symptom assessment. 
 
KEY POINTS: 
 Retrospective patient reports of irritable bowel syndrome symptoms are influenced by 
recall and ecological bias.  
 A digital patient-reported outcome measure (PROM) for momentary symptom 
assessment in irritable bowel syndrome, based on the experience sampling 
methodology, was developed, taking into account content validity and cross-cultural 
adaptation. 
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 The developed ESM-PROM assesses real-time symptoms and influencing factors in 
daily life, and therefore has the potential to provide insight into the fluctuating IBS 
symptom pattern during the day and to identify individual symptom triggers. 
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INTRODUCTION 
Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, characterized by 
recurrent abdominal pain and altered bowel habits. It affects up to 20% of the Western 
population, with a female predominance.(1-4) IBS leads to a reduction of quality of life, 
increased utilization of health care and higher (in)direct costs for society.(5, 6) Since specific 
biological markers are currently unavailable, IBS is a symptom-based diagnosis (7-10) and 
reliable symptom assessment methods are essential to investigate natural disease course and 
evaluate response to therapy.  
Both the United States Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) recommend the use of a composite primary endpoint for clinical trials, in which 
abdominal pain as well as stool consistency/frequency is addressed. With regard to abdominal 
pain, a seven-day mean score on an 11-point Numeric Rating Scale (NRS) assessed at the 
end of each day is recommended. However, both guidelines address the challenge of capturing 
all clinically important symptoms associated with IBS in a reliable measure of treatment benefit, 
since IBS is a heterogeneous disorder with diverse and fluctuating symptom patterns. 
Therefore, the development of a multi-item patient-reported outcome (PRO) instrument, that 
captures all clinically important symptoms of the IBS population, is recommended.(11, 12) 
Furthermore, currently recommended retrospective (i.e. end-of-day), self-reported outcomes 
have important limitations. First, there is a high risk for recall bias, since retrospective 
information consists of a reconstruction of a few specific moments rather than a reliable 
reflection of symptoms over a predefined period of time.(13-15) Second, it is well described 
that memory retrieval is influenced by the individual’s environment and mental state at the time 
of recall, known as ecological bias.(13, 14) In conclusion, retrospectively reported patient 
experiences about symptoms in the past can be significantly distorted.  
 
The Experience Sampling Method (ESM), also referred to as Ecological Momentary 
Assessment (EMA), may overcome these limitations. ESM is an electronic questioning method 
characterized by random, repeated assessments in the subject’s current state and 
environment for several consecutive days.(13, 14, 16) Hereby, ESM offers the opportunity to 
reduce the risk for recall and ecological bias and to capture symptom variability over time, 
while taking into account contextual, social and psychological factors, which might have an 
impact on IBS symptom reporting. ESM has been applied in a range of disorders, i.e. chronic 
pain, chronic fatigue and psychiatric disorders,(17-19) but has not been validated as a 
symptom assessment method for IBS. Only one study has been published reporting the use 
of ESM in an IBS population. Weinland et al. demonstrated that higher abdominal pain scores 
were reported in end-of-day diaries compared to ESM in IBS patients.(20) Additionally, our 
previously performed pilot trial on the correlation of Experience Sampling Method with currently 
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used retrospective patient-reported outcomes supported our hypothesis that ESM provides 
more accurate information about IBS symptoms.(21)  
 
The current report describes the development of a patient-reported outcome measure (PROM) 
for real-time measurement of abdominal and extra-abdominal symptoms, and their potential 
triggers, in IBS, using the ESM principle. In agreement with FDA guidelines on PROM 
development patient as well as expert input obtained by structured focus group interviews and 
expert meetings were used in the item selection process, herewith addressing content validity. 
Furthermore, cross-cultural adaptation was taken into account by performing cognitive 
interviews after forward-and-back translation of the developed instrument.(22) 
 
 
MATERIALS & METHODS 
Study Design 
The development of a novel PROM for symptom assessment in IBS, using the ESM principle, 
was performed in four phases: I) initial item selection, II) focus group interviews to obtain 
patients’ input, III) expert meetings to obtain the input of international experts in the fields of 
neurogastroenterology and motility and pain, and IV) translations and cognitive interviews to 
assure on patients’ understanding with the developed tool (cross-cultural adaptation). 
Throughout this report, the developed instrument will be referred to as ‘ESM-PROM’. 
 
Phase I: Item selection  
In our previous pilot study, real-time ESM was compared to retrospective paper symptom 
assessments in IBS patients.(21) The IBS-specific ESM items used in this study were based 
on a developed framework of theoretical constructs for symptom assessment in an IBS 
population. These IBS constructs were obtained from currently used retrospective symptom 
surveys and qualitative studies, selected after an extended literature search.(23-29) The ESM-
specific constructs, i.e. items regarding psychological status, social factors and context and 
environment at the moment of assessment, were derived from ESM questionnaires as used in 
previous studies at the department of Psychiatry of Maastricht University Medical Center + 
(Maastricht UMC+).(30, 31) Additionally, subjects, participating in the pilot study, gave their 
feedback about the feasibility and burden of ESM as an assessment tool and about the 
relevance of the items on the initial draft instrument (developed after first item selection). This 
feedback was taken into account for further selection. 
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Phase II: Focus group interviews  
Recruitment of focus group participants 
Subjects between the age of 18 and 75 years and diagnosed with IBS, according to the Rome 
III criteria (7-9), were recruited via the outpatient department of the Gastroenterology and 
Hepatology division of Maastricht UMC+ as well as general practitioner practices in South-
Limburg, the Netherlands. All subjects were previously included in the Maastricht IBS 
Cohort.(32, 33) Subjects with organic diseases possibly explaining the gastrointestinal 
symptoms, as diagnosed by a physician, were not eligible for inclusion. Furthermore, subjects 
with prior abdominal surgery (except appendectomy, laparoscopic cholecystectomy and 
hysterectomy) were not included. Participants needed to be able to understand written Dutch 
and speak the Dutch language, since focus groups were conducted in Dutch. All subjects gave 
written informed consent prior to participation. 
 
Conducting and moderating focus group interviews 
Focus group meetings were arranged in order to select a relevant set of items for real-time 
symptom assessment in IBS using ESM, according to patient opinions. Subjects eligible for 
participation were invited to Maastricht UMC+ to participate in a focus group interview. 
Meetings took 90 minutes and were planned one by one, each preferably including six to eight 
participants, continuing until saturation of input was reached. Saturation was determined as 
meetings no longer augmenting any new items or information in addition to previous 
meetings.(22, 34) Focus groups were guided by a moderator (LV) and at least one assistant-
moderator (ZM or DK) and were performed according to a predefined, two-stage framework, 
based on guidelines described in literature.(34-36) The first stage consisted of an open 
discussion, in which participants were instructed to bring forward every item they considered 
to be essential in an IBS symptom assessment tool aiming to get insight in their symptom 
pattern during daily life. This concept, rather than introducing specific items, was chosen to 
prevent bias to arise. During the second stage, participants were requested to criticize the ESM 
items, that were initially selected during phase I. We specifically asked them to argument which 
questions were relevant in a real-time symptom assessment method for IBS and which could 
be omitted to their opinion. Also, they were asked to define any incomprehensible items and 
to give their opinion about the most appropriate response scales.    
 
Analysis of focus group data 
Focus group discussions were recorded by video camera and additionally, attending 
investigators made notes. Video recordings were transcribed verbatim after the meetings and 
subsequently summarized in a spreadsheet database. In this, also the notes of the 
investigators and feedback of subjects in our previous pilot trial were added. Subsequently, 
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this spreadsheet was used to evaluate whether to preserve, modify, delete or add items from 
the questionnaire to develop a draft instrument. Results from all focus group meetings were 
combined in the spreadsheet and are presented together as the results of phase II in this 
report.  
 
Phase III: Expert meeting 
Investigators with extensive experience in the fields of neurogastroenterology and motility and 
pain were gathered to obtain expert opinions regarding the further development of the ESM-
PROM. The international experts were invited for a face-to-face meeting and were asked to 
discuss all items that were selected during initial item selection (phase I) and the focus group 
meetings (phase II). They specifically criticized the items on relevance in clinical practice (i.e. 
does an item add something to the insight in a patient’s symptom pattern and disease 
severity?) and suitability for a real-time symptom assessment method (i.e. will repeated, 
momentary assessment of this item result in measuring variability during the day?). On the 
basis of this discussion, a final set of questions was selected. The authors LV, DK, JK, CL, 
QA, MC, EQ and AM were present at the meeting and MS and DD gave their input via 
telephone conference.  
 
Phase IV: Translations and cognitive interviews 
In order to perform a further validation study in a multicenter, international context the ESM-
PROM, originally developed in Dutch, was translated into English and Swedish. Translation 
was performed using forward-and-back procedures, as described by the World Health 
Organization (WHO).(37) Additional individual cognitive interviews with native-speaking IBS 
patients were arranged with regard to each language (i.e. Maastricht UMC+ regarding Dutch, 
Queen Mary University of London regarding English and University of Gothenburg regarding 
Swedish) to verify patient understanding with the developed items in each language. 
Participants were instructed to read out loud all items and response scales and to communicate 
items or answers they did not understand. Furthermore, they were asked to identify any 
revisions that could make the instrument more appropriate. All cognitive interviews were 
transcribed independently and decisions about revisions were made separately for each 
language.  
Interviews were planned one by one continuing until saturation of input was reached. Inclusion- 
and exclusion criteria for participants in this phase of the project were similar to those described 
under ‘Phase II: Focus group interviews’.  
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RESULTS 
Study population 
Patient characteristics of all subjects that participated in the different phases of the project are 
summarized in Table 1. With regard to the focus group interviews a total of 67 patients 
diagnosed with IBS according to the Rome III criteria (7-9) were invited to one of the focus 
group sessions. Thirty-two of them agreed to participate, however, only seventeen subjects 
were in fact present during four different meetings. Reasons for cancelation were illness (n=6) 
and family circumstances (n=1). Two subjects did not inform us about their reason for 
cancelation and another six did not cancel at all.  
To take into account possible selection bias, demographical characteristics and symptom 
severity scores of the 17 focus group participants were compared to those of subjects, included 
in the Maastricht IBS cohort, that did not participate in the focus group meetings. Focus group 
participants were slightly older (median age 58.0 vs. 45.0 years, p<0.05), but no further clinical 
differences were found. Results are shown in Table S1.  
  
Phase I: Item selection 
The initially developed ESM instrument contained 60 items, based on five domains: physical 
status, defecation, mood, environmental & social context, and drug use. 
The twenty-six participants that completed ESM assessments during our previous pilot study 
were asked to evaluate practical issues of ESM as well as the relevance of all specific items 
on the instrument. With regard to practical aspects, a subset of the participants stated that the 
number (i.e. ten) of assessments during the day (n=14; 53.8%) and the time (i.e. ±5 minutes) 
spent completing each assessment (n=10; 38.5%) were quite burdensome. Furthermore, a 
few questions (mostly questions about psychological status, such as ‘I feel enthusiastic’ and ‘I 
feel strong’) were considered difficult to define, making these questions inappropriate for a 
PROM. In general, participants stated that questions about nutrition and relation between food 
and GI complaints should be included. The set of items constructed during phase I is shown 
in Table S2. 
 
Phase II: Focus group interviews 
Focus group interviews resulted in a reduction of the number of items from 60 on the initial 
draft instrument to 42, with some slight modifications to the five domains: physical status, 
defecation, mood and psychological factors, context and environment, nutrition and drug use 
(Figure 1). The suggested modifications regarding each domain are summarized below. The 
resulting set of items is shown in Table S3. 
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Physical status 
Participants emphasized that abdominal pain is one of the most important symptoms to assess 
and they agreed on two essential elements in a real-time symptom assessment method; 
location and character of the pain. For pain location, all subjects supported the concept of a 
schematic picture of the abdomen in which they can indicate a particular abdominal region. 
One participant noted that it might be confusing which side of the picture reflects the left versus 
the right side of the abdomen, so it is important to clearly point this out within the picture (Figure 
2). Furthermore, it was stated that it should be possible to indicate more than one abdominal 
region at a time. For assessment of the character of the pain participants suggested to insert 
several categories of which patients can choose one or more suitable categories for their pain 
at that moment. Suggested categories were cramp-like, sharp, stabbing, dull and bruise-like. 
Moreover, subjects agreed that it is important to assess whether the abdominal pain is 
continuous and prolonged or acute and short lasting. 
In addition to abdominal pain, subjects agreed on the importance of scoring and reporting other 
GI symptoms associated with IBS: bloating, visible abdominal distension, abdominal rumbling, 
flatulence, belching, nausea and heartburn. Further, non-abdominal complaints as stated in 
the draft instrument (i.e. dizziness, palpitations, shortness of breath and sweating) were 
considered relevant for the majority of participants.   
Lastly, fatigue, general illness (i.e. chill, the flu, fever) and comorbid symptoms were mentioned 
as possible factors provoking IBS symptoms. Regarding questioning methods, participants 
suggested solely asking after these conditions without suggesting any association with IBS 
symptoms, i.e. ‘Do you feel tired?’ instead of ‘Do you think fatigue is influencing your IBS 
symptoms at this moment?’ Since comorbid symptoms can be very widespread, a momentary 
question could be ‘Do you have complaints of comorbid symptoms right now?’, with answers 
on a Likert scale.  
 
Defecation 
Assessment of several aspects of bowel habits was considered essential since irregular 
bowel patterns can be one of the main symptoms itself as well as be associated with and 
influence abdominal symptoms. Regarding defecation, the participants came up with at least 
three essential elements: frequency, stool form and urgency. Frequency can be assessed 
asking ‘how many times did you defecate since the previous assessment?’ and answering 
using categories, i.e. 0 times, 1 time, etcetera. Participants concluded that stool form is 
properly assessed using the Bristol Stool Form Scale (BSFS) for each time of defecation, 
which they are familiar with due to existing symptom surveys they have completed before. 
Other items that were raised as potentially of relevance, but not essential, are painful and 
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difficult defecation, whether or not being able to postpone defecation in case of urgency and 
bloody or mucinous stool. 
The items about defecation on the initial draft instrument were considered relevant, but were 
lacking the possibility to report the frequency of defecation since the previous assessment. 
Therefore, subjects suggested asking after defecation frequency and subsequently 
consistency according to the BSFS (for each reported defecation). Furthermore, nearly all 
subjects agreed on the relevance of adding an item regarding the degree of fecal urgency and 
about whether the abdominal complaints did diminish after defecation. A few aspects of 
defecation were proposed by small subsets of participants, i.e. bloody stool (n=1), mucus in 
stool (n=2), painful defecation (n=3) and whether patients were able to postpone a bowel 
movement (n=3). 
The last comment with regard to defecation was that in some cases having a bowel movement 
relieves the abdominal symptoms. Therefore, participants suggested adding a question asking 
‘Did having a bowel movement relieve your abdominal complaints?’ 
 
Mood and psychological factors 
All participants agreed on the importance of assessing psychological factors given the often-
experienced association between for instance negative emotions, fear for developing 
abdominal complaints or stress in general and IBS symptomatology. Furthermore, given the 
possibility that ESM offers to simultaneously assess for social, environmental and 
psychological features at the moment of symptom reporting (i.e. to overcome ecological bias 
as well as to evaluate for factors of influence on IBS symptoms), it is essential to include 
psychological items in the instrument. In total, ten items regarding a person’s current mood or 
mental status were selected from the initial draft instrument. Additionally, an eleventh item, ‘I 
feel good right now’, was considered relevant.  
 
Context and environment 
Participants stated that the presence or experienced severity of IBS symptoms at a certain 
moment can depend on the concerning situation and therefore, as psychological factors, also 
contextual and environmental factors at the moment of assessment were considered relevant. 
Items ‘Where am I?’, ‘Who is with me?’ and ‘What am I doing?’ were therefore kept in the 
instrument (including the answer options). Additionally, all four focus group meetings resulted 
in adding one extra question in this section: ‘My symptoms are limiting my current activities.’ 
In total, based on input from the participants, this section is left with ten relevant items.  
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Nutrition and drug use 
Participants stressed that diet should be taken into account when assessing IBS symptoms 
and associated factors. Two components of nutrition were found to be essential, namely 
specific food items that may provoke symptoms and regularity in dietary pattern. Subjects 
suggested to insert a question about what someone ate, i.e. ‘What did you eat since the last 
beep?’, with categorical answers, in which more than one answer is possible at a time. 
Categories could be: carbohydrates, dairy products, spicy foods, fatty foods, onions/leek, 
cabbage, fruits, sweets, carbonated beverages and nuts. The participants were not able to 
suggest the best way to assess the regularity of the dietary pattern. Some suggested to insert 
a question asking ‘How much did you eat since the last beep signal?’ with answers on a Likert 
scale, in which the mean score is a normal amount of food for that particular person. Therewith, 
patients can score whether they ate less or more than what is usual for them. 
With regard to drug use several important factors were determined: coffee, tea, alcohol, 
nicotine and medication use. Obviously, regular medication use should not be included in the 
momentary assessments, but subjects stated that it is important to ask whether patients used 
any occasional drugs. Answers could be categorical, i.e. painkillers, antacids, 
spasmolytics/antispasmodics, laxatives and antidiarrheals.   
 
Practical issues 
Lastly, we asked participants to discuss some practical issues concerning ESM. Most 
frequently discussed were the number of assessments per day and the acceptable time spent 
completing the assessments. Some subjects stated that 10 times a day, with 3 to 5 minutes 
per assessment would be acceptable. However, frequently, participants stated that this would 
not be possible for them due to their occupational situation. Some stated that 6 times a day 
during 5 minutes might be possible, but that there should be a longer period of time in which a 
person can respond after the beep signal. For example, it would be advisable to have the 
questions accessible for one hour after the signal, rather than only for 10 minutes.  
Furthermore, the possibility of standard personalized answers was discussed. Participants 
raised the option of keeping former answers to the next assessment moment, so that questions 
have to be completed only in case of changes since the previous assessment. This might 
decrease the time needed for each participant.    
 
Phase III: Expert meeting 
All 42 items resulting from the previous phases of the project were discussed with regard to 
relevance in a momentary assessment method. It is important to emphasize that the developed 
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ESM-PROM concerns not only real-time assessments of IBS symptomatology, but additionally 
takes into account momentary aspects, as contextual and psychological factors, regarding the 
moment of symptom reporting. Regarding abdominal pain, experts concluded that character 
of abdominal pain is less relevant to be assessed ten times a day. Therefore, it was concluded 
that severity and location of abdominal pain should be included as the only abdominal pain-
relating items. Some nuances were added with regard to the GI symptoms, such as besides 
asking solely for the severity of bloating, it was suggested also to assess whether this is 
associated with a feeling of discomfort and whether this is accompanied by visible distension 
of the abdomen. The latter was also mentioned during focus group interviews.  
Regarding comorbid symptoms as “feeling tired” and “general illness”, as were mentioned 
during the focus group interviews, experts agreed that those are not suitable for momentary 
assessments per se. Comorbid symptoms should rather be assessed cross-sectionally, as 
fatigue and general illness are not likely to change very much during the day. Therefore, those 
items were not included in the ESM-PROM.  
With regard to bowel movements, frequency, stool form and fecal urgency were included as 
the most important items. Furthermore, straining and (in)complete evacuation were added in 
case a bowel movement is reported. Other issues regarding defecation were not included. 
Focus group participants mentioned that it is important to ask whether the severity of 
abdominal complaints decreased after a bowel movement. However, it was decided that this 
is not a momentary question and that ESM itself offers the opportunity to evaluate a possible 
association (relief as well as aggravation of abdominal pain before or following a bowel 
movement) between bowel movements and abdominal symptoms by repeated measurements 
over the day. 
The ten items regarding psychological status, resulting from focus group interviews, were 
thoroughly discussed, since experts stated that ten items would be too much of a burden with 
respect to the time needed to complete one assessment. Therefore, this was reduced to seven 
items, including both positive and negative affect. Contextual items were discussed as well, 
but were not changed.  
Experts all agreed that nutritional factors are of important interest with regard to IBS symptoms. 
However, it was discussed that the explicit evaluation of associations between GI symptoms 
and specific food products is beyond the scope of the current project. Including items on 
specific nutritional factors would result in too many items. Therefore, it was decided to only 
include an item on whether or not someone ate between the current and the previous 
assessment in order to evaluate a possible role for food intake in individual IBS 
symptomatology. 
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With respect to the practical issues that were raised during focus group meetings, several 
options to change the number of assessments during the day and the time during which an 
assessment is available after each beep were considered. Since in our pilot study(21) median 
response time after the signal was 21 seconds (IQR: 11 – 40 seconds) and in only 0.7% of 
total assessments response time was longer than 10 minutes, it was decided that extending 
this time period would probably not result in a much higher response rate. Furthermore, the 
total compliance rate with ten assessments each day of 76.8%, i.e. on 76.8% of the total days 
at least six assessments were completed, was considered high. Therefore, it was decided not 
to change both of these practical features.      
In conclusion, experts’ opinions resulted in a further reduction of the number of items to 32, 
categorized into the same domains as discussed before. The final instrument, as developed in 
phase III, is shown in Table S4.  
 
Phase IV: Translations and cognitive interviews 
Demographic characteristics of the participants in each center are shown in Table 1. Cognitive 
interviews did not reveal any large-scale problems regarding the patients’ understanding of the 
instrument. With respect to the Dutch instrument only a few modifications were suggested in 
order to verify the patients’ understanding. No adjustments were made to the content or the 
order of the items. The English as well as Swedish instrument needed some modifications with 
respect to wording after the translation. Also, a few items were adapted to make them more 
suitable for momentary assessments. Besides these minor changes no alterations of content 
or order of items were done. 
 
 
 
 
 
 
 
 
 
DISCUSSION 
The current study was conducted as part of a multicenter project aiming to develop and validate 
a new patient-reported assessment tool for real-time evaluation of IBS symptoms.  Given the 
lack of biological markers for IBS, evaluation of potential interventions aimed at symptom 
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improvement is dependent on symptom assessments by using patient-reported outcome 
measures.(25, 38) The current lack of a reliable symptom assessment method, that considers 
all clinically important signs and symptoms of IBS, requires development of a new multi-item 
tool.(11, 12, 29)  
 
The PROM development in this study was executed according to FDA guidelines and the NIH 
Patient Reported Outcome Measurement Information System (PROMIS) consortium, 
recommending PRO instruments to be developed according to a conceptual framework with 
obtaining patient input to ensure content validity and reliability.(22, 23, 25) The development 
was therefore performed in four consecutive phases: initial item selection from literature, 
obtaining patients’ input by structured focus group interviews, considering experts’ opinions by 
an (international) expert meeting and cognitive interviewing with IBS patients after forward-
and-back translation. 
 
Focus group interviews revealed a broad spectrum of items that, according to the participants, 
are relevant for a momentary IBS-specific PROM. After transcription of focus group 
discussions, a total of 42 items and another 21 optional items were defined. Optional items 
comprised questions suggested or defined as relevant only by a subset of the participants. All 
defined items were understandable for the total focus group population, positively contributing 
to content validity. Since in the experience sampling methodology momentary assessments 
are collected ten times a day, the number of instrument items should be limited in order to 
reduce patient burden and thereby maintain patient compliance. Although compliance with 
ESM was reasonably good (76.8%) in our pilot study using an ESM instrument containing as 
much as 60 items, ideally, each assessment should take no longer than 2 minutes.(30) 
Therefore, selected items were reviewed by an international expert team in the fields of 
neurogastroenterology and motility, leading to further selection. Finally, a momentary 
questionnaire containing 32 items was developed.  
 
Items could be clustered into five categories: physical status, defecation, mood and 
psychological factors, context and environment, and nutrition and drug use. The categories 
“physical status” (including abdominal symptoms) and “defecation” are the key-elements in 
actual IBS symptom assessment, whereas the other three categories are aiming to evaluate 
influencing factors of these symptoms. Specifically, the items covered by “mood and 
psychological factors” will give insight into a possible link between mental disturbances and 
IBS symptoms, taking into account the individual moment-to-moment variability of both 
aspects. Likewise, “context and environment” can be linked to symptom severity, herewith 
taking into account possible effects of ecological factors on symptom response. “Nutrition and 
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drug use” were raised among the most important daily life elements influencing GI symptoms. 
To assess the effect of these possible influencing factors on GI symptoms, multivariate and 
multilevel analytical techniques will be required.(30, 39)   
 
Several PROM’s for IBS symptom assessment have been developed recently. Spiegel and 
colleagues delineated a conceptual framework for IBS-PROM’s, consisting of 35 items, 
subdivided over four GI-related domains and an extra-intestinal domain.(23) These five 
categories are also represented in our ESM-PROM, however, not all individual items have 
been implemented. All items were discussed during focus group meetings, but given the 
repeated character of ESM, in particular items regarding symptom-bothersomeness, -
interference, -impact and -predictability were thought less suitable for the ESM-PROM. 
The PROMIS consortium has developed the PROMIS GI symptom scale, which consists of 
short outcome measures for eight GI symptom complexes.(25) All symptom complexes, but 
‘disrupted swallowing’ and ‘bowel incontinence/soilage’, are taken into account in the ESM-
PROM. Focus groups revealed that problems with swallowing are not very frequently 
encountered in the context of IBS. Bowel incontinence might occur, but was not reported by 
the majority of IBS patients and was therefore thought not generalizable to the target 
population of the ESM-PROM.  
Recently, the ‘Diary for Irritable Bowel Syndrome Symptoms’ was developed by the Patient-
Reported Outcome Consortium IBS Working Group (PRO Consortium IBS-WG).(40) The 
conceptual framework for this 24-hour diary is based on two core symptoms: abdominal 
symptoms and bowel movement-related symptoms. Of the elicited specific items, abdominal 
discomfort and abdominal cramping are not included in our ESM-PROM, since these were 
found difficult to differentiate from abdominal pain – in line with recent Rome IV definitions. 
Therefore, these items will not add considerable extra information and were omitted in order 
to reduce the number of items.  
All in all, the differences between the ESM-PROM and previously developed PROM’s for IBS 
mainly relate to differences in methodology and the fact that ESM concerns repeated 
assessments over the day.  
 
Next to the items, also possible scoring scales for all items were discussed. Participants 
supported the use of a Numeric Rating Scale, but could not agree on seven (as formerly used 
in ESM (30)) or eleven endpoints. In comparison, the PROMIS scales make use of a 5-point 
Likert scale (41), however, an end-of-day 11-point NRS is currently recommended by the FDA 
and EMA (European Medicines Agency) as a primary endpoint in IBS clinical trials (11, 12). In 
order to prevent confusion by using different response scales, this scale was chosen to be 
incorporated into the instrument for all items. 
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A number of study limitations ought to be noted. First, the risk of self-selection (sampling) bias, 
i.e. the participants’ decision whether or not to participate may influence the 
representativeness of the study population. As an example, subjects with a stronger opinion 
than others or with more severe symptoms might be more willing to participate in the focus 
group meetings. Furthermore, only 53% (17/32) of the initially attending participants of the 
focus groups did eventually participate. However, since the Maastricht IBS cohort concludes a 
large heterogeneous IBS population, we expect to cover this heterogeneity even in this small 
subset of the population. Additionally, possible differences between subjects who did 
participate in the focus group meetings and subjects who did not, were explored. As shown in 
Table S1 no statistically significant differences in demographical characteristics or symptom 
severity scores, possibly indicating self-selection bias, were demonstrated. It appears that 
focus group participants less often scored positive for depressive symptoms on the HADS, 
using a cut-off of ≥8, and showed a slightly higher Mental Composite Score on the SF-36, than 
the subjects who did not participate in focus group meetings. Though these differences were 
not statistically significant, this may indicate that the focus group population did not perfectly 
reflect the heterogeneity of the general IBS population with regard to mental health. However, 
since the HADS is a screening tool using a cut-off value, a score <8 does not mean that no 
depressive symptoms were present in our population at all. Furthermore, participants agreed 
on the importance of assessing psychological factors additionally to GI symptoms, and 
therefore, we are confident that the content of the developed ESM-PROM includes the relevant 
questions for symptom assessment in IBS patients. Another limitation might be the distribution 
of IBS subtypes amongst the participants, since only 12% (2/17) of subjects were defined as 
constipation-predominant IBS (IBS-C). Nevertheless, we believe that constipation-associated 
symptoms will as well be experienced by mixed-type (IBS-M) patients and so, we expect to 
have captured both diarrhea- and constipation-associated symptoms. Also, during the 
cognitive interviews IBS-C patients were attending and did not mention a lack of any 
constipation-specific items.              
 
The number of subjects attending focus group meetings should be mentioned. The relatively 
small number of participants per focus group (i.e. 6-8) was chosen, since it is considered to 
invite all subjects to actively participate in the discussion on the one hand and to gain a variety 
of perspectives on the other hand.(42) Furthermore, as discussed previously in this report, 
focus group meetings were arranged one by one until reaching saturation of input after four 
meetings and therefore, we feel that the total sample of 17 participants suffices with regard to 
this project. To date, successful focus group studies with similar sample sizes have been 
reported previously.(35, 43) Likewise, rather small numbers of participants were included for 
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the cognitive interviews in each center, however, also in this phase of the project saturation of 
input was ensured. Since focus groups and the expert meeting already determined the content 
of the tool, cognitive interviews were particularly intended to evaluate patients’ understanding 
with the individual items of the ESM-PROM with regard to linguistic issues (i.e. after forward-
and-back translation). Therefore, the resulting number of cognitive interviews per center meets 
our expectations. With regard to level of education and employment status, the Dutch 
participants reflect the general Dutch population quite well. The Swedish and English 
participants were, however, relatively highly educated. This should be taken into account when 
recruiting subjects for future studies regarding the developed questionnaire, since extra 
instructions on how to interpret and answer the questions might be needed in lower educated 
individuals.   
 
In conclusion, we here report on the development of a disease-targeted PROM suitable for 
real-time assessment of abdominal pain and other gastrointestinal symptoms as well as daily 
life factors that may influence IBS symptoms. A smartphone application has been specifically 
developed to implement this PROM and future research will comprise further, multicenter 
validation of this instrument, with regard to the different languages and cross-cultural aspects. 
ESM appears particularly suitable for the evaluation of individual symptom patterns over the 
course of a predefined period of time and the identification of specific triggers of gastrointestinal 
symptoms in daily life. It can hereby function in supporting diagnostic as well as therapeutic 
trajectories, in clinical practice. Moreover, once ESM is demonstrated to be a valid and reliable 
PRO instrument in this particular context, it can be implemented in clinical research to assess 
the effect of therapeutic interventions in IBS and to stratify IBS patients based on their 
symptoms. 
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TABLES 
 
Table 1: Patient characteristics of subjects that participated in the different phases of the project. 
 Focus group 
interviews 
Netherlands 
N=17 
Cognitive 
interviews, 
Netherlands 
N=5 
Cognitive 
interviews, 
Sweden 
N=6 
Cognitive 
interviews, 
UK 
N=6 
Age, median [IQR] 58.0 [39.5 – 63.0] 49 [24.5 – 57.5] 37.5 [31.0 – 64.25] 34 [22.5 – 44.0] 
Female, n (%) 13 (76.5) 4 (80) 3 (50) 3 (50) 
IBS-subtype, n (%) 
IBS-D 
IBS-C 
IBS-M 
IBS-U 
 
8 (47.0) 
2 (11.8) 
7 (41.2) 
0 
 
2 (40) 
2 (40) 
1 (20) 
0 
 
0 
2 (33.3) 
4 (66.7) 
0 
 
2 (33.3) # 
1 (16.7) # 
1 (16.7) # 
0 # 
Level of education 
Primary 
Secondary 
University 
 
1 (5.9) # 
12 (70.6) # 
2 (11.8) # 
 
 
4 (80.0) # 
 
 
 
 
6 (100) 
 
 
1 (16.7) 
5 (83.3) 
Work status 
School/student 
Employed 
Unemployed 
Retired 
 
 
8 (47.1) # 
4 (23.5) # 
3 (17.6) # 
 
 
2 (40.0) # 
2 (40.0) # 
 
 
5 (83.3) # 
 
# 
# 
# 
# 
# Data of other participants are missing. 
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FIGURES 
 
 
Figure 1: Framework of the developed PROM, consisting of 25 items (in the figure summarized in 10 constructs) based on five 
domains.   
 
 
Figure 2: Picture on which subjects can indicate the location of abdominal pain according to nine abdominal regions.  
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Table S1: Demographical characteristics and symptom severity scores of participants of the Maastricht IBS-
cohort, separate for ‘focus group participation’ versus ‘no focus group participation’.   
Maastricht IBS Cohort 
 Focus group participation  
(n=17) 
No focus group participation  
(n=412) 
Female sex, n (%) 13 (76.5) 295 (71.6) 
Age, median [IQR] 58.0 [39.5 – 63.0] 45.0 [28.0 – 59.0]* 
BMI, median [IQR] 26.5 [22.2 – 30.9] 24.1 [21.5 – 27.4] 
IBS Subtype, n (%) 
IBS-D 
IBS-C 
IBS-M 
IBS-U 
 
8 (47.1) 
2 (11.8) 
7 (41.2) 
0 
 
135 (32.8) 
  82 (19.9) 
169 (41.0) 
  26   (6.3) 
14-day mean symptom score,  
median [IQR] 
Abdominal pain 
Abdominal discomfort 
Abdominal bloating 
Constipation 
Diarrhea 
 
 
2.14 [1.64 – 2.64] 
2.29 [2.04 – 2.69] 
2.07 [1.72 – 2.46] 
1.07 [1.00 – 1.59] 
1.14 [1.00 – 1.48] 
 
 
2.21 [1.57 – 2.86] 
2.36 [1.92 – 2.93] 
2.09 [1.50 – 2.86] 
1.29 [1.00 – 1.89] 
1.21 [1.07 – 1.67] 
HADS, n (%) 
Depression ≥8 
Anxiety ≥8 
 
1 (5.9) 
5 (29.4) 
 
  86 (20.9) 
154 (37.4) 
SF-36, median [IQR] 
Physical Composite Score (PCS) 
Mental Composite Score (MCS) 
 
41.21 [36.05 – 53.18] 
54.34 [47.30 – 56.97] 
 
42.63 [33.99 – 49.60] 
48.67 [39.85 – 55.41] 
Differences tested using Mann-Whitney U test for continuous data and χ2- or Fisher’s exact test for categorical 
data. 
* Significant difference between ‘focus group participation’ and ‘no focus group participation’ (p<0.05).  
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Table S2: Set of items for the ESM-PROM developed during phase I: Initial item selection. 
Phase I: Initial item selection 
  Physical status Answer scale 
1 I feel hungry 1 (none) - 7 (very much) 
2 I feel tired 1 (none) - 7 (very much) 
3 I do not feel well 1 (none) - 7 (very much) 
4 I am having palpitations 1 (none) - 7 (very much) 
5 I am sweating 1 (none) - 7 (very much) 
6 I feel numbness/tingling 1 (none) - 7 (very much) 
7 I am short of breath 1 (none) - 7 (very much) 
8 I have a choking sensation 1 (none) - 7 (very much) 
9 I feel chest pain 1 (none) - 7 (very much) 
10 I feel dizzy 1 (none) - 7 (very much) 
11 I am having hot flashes 1 (none) - 7 (very much) 
12 I am having chills 1 (none) - 7 (very much) 
13 I feel upper abdominal pain 1 (none) - 7 (very much) 
14 I feel lower abdominal pain 1 (none) - 7 (very much) 
15 I am feeling heartburn 1 (none) - 7 (very much) 
16 I am feeling sick 1 (none) - 7 (very much) 
17 I feel bloated 1 (none) - 7 (very much) 
18 I am having intestinal gas 1 (none) - 7 (very much) 
19 I am suffering from burping 1 (none) - 7 (very much) 
20 
I have been physically active since the previous beep 
signal 
1 (none) - 7 (very much) 
  Defecation   
21 Have you defecated since the previous beep signal? Yes / No 
22 If yes, what did the stool look like? Bristol Stool Score 1 - 7 
  Mood   
23 I feel enthusiastic 1 (none) - 7 (very much) 
24 I feel sad 1 (none) - 7 (very much) 
25 I feel irritated 1 (none) - 7 (very much) 
26 I feel content  1 (none) - 7 (very much) 
27 I feel stressed 1 (none) - 7 (very much) 
28 I feel restless 1 (none) - 7 (very much) 
29 I feel happy 1 (none) - 7 (very much) 
30 I feel lonely 1 (none) - 7 (very much) 
31 I feel strong 1 (none) - 7 (very much) 
32 I feel anxious 1 (none) - 7 (very much) 
33 I feel relaxed 1 (none) - 7 (very much) 
34 I feel worried 1 (none) - 7 (very much) 
35 I feel inspired 1 (none) - 7 (very much) 
36 I feel disappointed 1 (none) - 7 (very much) 
37 I feel insecure 1 (none) - 7 (very much) 
38 I feel cheerful 1 (none) - 7 (very much) 
39 I feel guilty 1 (none) - 7 (very much) 
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 Mood (continued)   
40 I am afraid to lose self-control  1 (none) - 7 (very much) 
41 I can not drop my thoughts 1 (none) - 7 (very much) 
42 I am worrying 1 (none) - 7 (very much) 
43 Overall, I feel good  1 (none) - 7 (very much) 
  Environmental and social context   
44 Where am I? 
At home, at someone 
else’s house, work/school, 
public place, on the go, 
somewhere else 
45 Who is with me? 
Partner, friends, residents, 
colleagues, family (not 
residents), acquaintances, 
unknown/others, nobody   
46 I find their company pleasant 1 (none) - 7 (very much) 
47 I feel accepted 1 (none) - 7 (very much) 
48 I feel uncomfortable in this situation 1 (none) - 7 (very much) 
49 I would rather be alone 1 (none) - 7 (very much) 
50 We are doing something together 1 (none) - 7 (very much) 
51 
 
What am I doing (right before the beep)? 
Resting, work/school, 
housekeeping/grocery, 
hygiene/self-care, 
eating/drinking, relaxing, 
something else  
52 I would rather like to do something else 1 (none) - 7 (very much) 
53 I am active right now 1 (none) - 7 (very much) 
54 I like to do this activity 1 (none) - 7 (very much) 
55 It takes effort to do this 1 (none) - 7 (very much) 
56 I am good at this 1 (none) - 7 (very much) 
57 This is a challenge for me 1 (none) - 7 (very much) 
  Think of the most important event since the previous beep signal: 
58 This event was: 
 -3 (very unpleasant) –  
3 (very pleasant)  
59 
This event was: 
-3 (very unimportant) –  
3 (very important)  
  Drug use   
60 I used … since the previous beep signal 
Caffeine, nicotine, 
medication, alcohol, 
cannabis, other drugs, 
none of those 
Red color indicates items that were removed from the instrument during phase II: Focus group interviews.   
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Table S3: Set of items for the ESM-PROM, adjusted according to patients’ input during phase II: Focus group 
interviews. 
Phase II: Focus group interviews 
 Physical status Answer scale 
1 I feel hungry 0 (none) - 10 (very much) 
2 I feel tired 0 (none) - 10 (very much) 
3 I am having palpitations 0 (none) - 10 (very much) 
4 I am sweating 0 (none) - 10 (very much) 
5 I am short of breath 0 (none) - 10 (very much) 
6 I feel dizzy 0 (none) - 10 (very much) 
7 I am having abdominal pain 0 (none) - 10 (very much) 
7a 
This pain is located in the following part(s) of my 
abdomen Figure abdominal regions 
8 I am feeling heartburn 0 (none) - 10 (very much) 
9 I am feeling sick 0 (none) - 10 (very much) 
10 My abdomen feels bloated 0 (none) - 10 (very much) 
11 I am having intestinal gas 0 (none) - 10 (very much) 
12 I am suffering from burping 0 (none) - 10 (very much) 
13 
I am having rumbling sounds coming from my 
abdomen 
0 (none) - 10 (very much) 
14 
I have been physically active since the previous beep 
signal 
0 (none) - 10 (very much) 
 Defecation   
15 
How many times did you open your bowels since the  
previous beep signal? 
0, 1, 2, 3, 4, more than 4 
times 
16 What did the stool look like? Bristol Stool Score 1 - 7 
17 
I have felt an urge to open my bowel since the 
previous beep signal 
0 (none) - 10 (very much) 
18 
The bowel movement(s) was/were associated with a 
relief of my abdominal symptoms 
0 (none) - 10 (very much) 
19 
I have been able to postpone a bowel movement since 
the previous beep signal 0 (none) - 10 (very much) 
 Mood and psychological factors   
20 I feel sad 0 (none) - 10 (very much) 
21 I feel irritated 0 (none) - 10 (very much) 
22 I feel content 0 (none) - 10 (very much) 
23 I feel stressed 0 (none) - 10 (very much) 
24 I feel lonely 0 (none) - 10 (very much) 
25 I feel anxious 0 (none) - 10 (very much) 
26 I feel relaxed 0 (none) - 10 (very much) 
27 I feel insecure 0 (none) - 10 (very much) 
28 I feel cheerful 0 (none) - 10 (very much) 
29 I am worrying 0 (none) - 10 (very much) 
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 Context and environment   
30 Where am I? 
At home, at someone 
else’s house, work/school, 
public place, on the go, 
somewhere else 
31 Who is with me? 
Partner, friends, residents, 
colleagues, family (not 
residents), acquaintances, 
unknown/others, nobody   
32 I find this company (un)pleasant 
 -5 (very unpleasant) – 5 
(very pleasant)  
33 I find this situation (un)pleasant 
 -5 (very unpleasant) – 5 
(very pleasant)  
34 I feel (un)comfortable in this situation 
 -5 (very uncomfortable) – 
5 (very comfortable) 
35 What am I doing (right before the beep)? 
Resting, work/school, 
housekeeping/grocery, 
hygiene/self-care, 
eating/drinking, relaxing, 
sports, something else  
36 I like to do this activity 0 (none) - 10 (very much) 
37 
My complaints restrict me in doing my normal activities 
right now 
0 (none) - 10 (very much) 
  
Think of the most important event since the previous 
beep signal:   
38 This event was: 
 -5 (very unpleasant) – 5 
(very pleasant)  
39 This event was: 
 -5 (very unimportant) – 5 
(very important)  
 Nutrition and drug use   
40 I used … since the previous beep signal 
Caffeine (coffee) / theine 
(tea), nicotine (smoking), 
medication, alcohol, drugs,  
none of those  
40a This was following medication: 
Medication for abdominal 
pain, other pain relief, 
medication for stomach 
acidity, medication for 
nausea, medication to 
stop diarrhea, medication 
for constipation, 
something else 
41 I ate … since the previous beep signal 
Wheat, spicy food, fatty 
food, cabbage/leek/onion,  
dairy products, none of 
these 
42 I ate .. ago 
Less than 15 min; 15-30 
min; 30 min-1 hr;  
more than1 hr 
 
Green color indicates items that were newly added to the instrument during phase II: Focus group interviews.  
Red color indicates items that were removed from the instrument during phase III: Expert meeting. 
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Table S4: Set of items for the ESM-PROM, adjusted according to experts’ input during phase III: Expert meeting. 
Phase III: Expert meeting 
  Physical status Answer scale 
1 I am having abdominal pain 0 (none) - 10 (very much) 
1a 
This pain is located in the following part(s) of my 
abdomen: Figure abdominal regions 
2 I am having intestinal gas 0 (none) - 10 (very much) 
2a The intestinal gas is causing discomfort 0 (none) - 10 (very much) 
3 
I am having rumbling sounds coming from my 
abdomen 0 (none) - 10 (very much) 
4 My abdomen feels bloated 0 (none) - 10 (very much) 
4a The bloating makes me feel uncomfortable 0 (none) - 10 (very much) 
4b The bloating is accompanied by a swollen abdomen 0 (none) - 10 (very much) 
5 I have the urge to open my bowels 0 (none) - 10 (very much) 
6 I am feeling sick 0 (none) - 10 (very much) 
7 I am suffering from burping 0 (none) - 10 (very much) 
8 I am feeling heartburn 0 (none) - 10 (very much) 
9 I am feeling full 0 (none) - 10 (very much) 
10 I am having palpitations 0 (none) - 10 (very much) 
11 I am sweating  0 (none) - 10 (very much) 
12 I am short of breath 0 (none) - 10 (very much) 
13 I feel dizzy 0 (none) - 10 (very much) 
14 My muscles are hurting 0 (none) - 10 (very much) 
15 My joints are hurting 0 (none) - 10 (very much) 
16 I feel an urge to pass urine 0 (none) - 10 (very much) 
  Defecation   
17 
Since the last beep, I have had the feeling that I had 
to open my bowels ... time(s) 
0, 1, 2, 3, 4, more than 4 
times 
17a 
Since the last beep, I have actually opened my 
bowels ... time(s) 
0, 1, 2, 3, 4, more than 4 
times 
17aI  It looked like this: ... Bristol Stool Score 1 - 7 
17aII I had to strain 0 (none) - 10 (very much) 
17aIII It feels like my bowels are not completely empty 0 (none) - 10 (very much) 
  Mood and psychological factors   
18 I am feeling good 0 (none) - 10 (very much) 
19 I am feeling low 0 (none) - 10 (very much) 
20 I am feeling anxious 0 (none) - 10 (very much) 
21 I am feeling irritated 0 (none) - 10 (very much) 
22 I am feeling stressed 0 (none) - 10 (very much) 
23 I am feeling relaxed 0 (none) - 10 (very much) 
24 I am worried 0 (none) - 10 (very much) 
  Context and environment   
25 Where am I? 
At home, at someone 
else's home, work/school, 
public place, on my way, 
somewhere else 
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 Context and environment (continued)  
26 What am I doing (just before the beep)? 
Resting, work/school work, 
household work/shopping, 
hygiene/self-care, 
eating/drinking, 
relaxing/recreation,  
sports, travelling, 
something else 
27 I feel (un)comfortable doing this 
 -5 (extremely 
uncomfortable) –  
  5 (extremely comfortable) 
28 My symptoms are limiting my current activities 0 (none) - 10 (very much) 
29 Who is with me? 
Partner/children, friends, 
housemates, colleagues, 
family (other than those 
who live in your house), 
acquaintances, 
strangers/others, no one 
29a I find this company (un)pleasant 
 -5 (extremely unpleasant) 
- 5 (extremely pleasant) 
  Nutrition and drug use   
30 I have eaten ... since the last beep 
Breakfast, lunch, dinner, a 
snack, none of these 
31 I ate ... ago 
More than 15 min., 15–30 
min.,  
30 min.-1 hour, more than 
1 hour 
32 Since the last beep I have used ...  
Caffeine (coffee) / theine 
(tea), nicotine (smoking), 
alcohol, drugs, medication, 
none of these 
32a This was following medication: 
Medication for abdominal 
pain, other pain relief, 
medication for stomach 
acidity, medication for 
nausea, medication to 
stop diarrhea, medication 
for constipation,  
something else 
 
Green color indicates items that were newly added to the instrument during phase III: Expert meeting.  
 
 
 
